Loading quotes...
Forecast
The analysts' average price target is €12.34 (+80.15%). The median is €13.65 (+99.27%).
| Buy |
Â
15 |
| Hold |
Â
6 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Iovance Biotherapeutics raises annual guidance after strong demand for Amtagvi and Proleukin
Strong market demand for the cancer therapies Amtagvi (Lifileucel) and Proleukin has led Iovance Biotherapeutics to significantly raise its annual forecast. The company is expanding its TIL therapy platform and broadening the clinical pipeline for additional solid tumors. Despite a weak overall market, investors are drawing the stock higher, signaling company-specific momentum. » More on finanzen.net
Iovance raises 2026 revenue forecast after strong demand for Amtagvi
Iovance raised its 2026 revenue forecast to $410–420 million, supported by rising U.S. demand for Amtagvi and Proleukin. Shorter production times and more than 110 treatment centers are driving growth and pushed the stock up about 10% to a 52-week high. The business remains based on tumor-infiltrating lymphocytes (TIL), which are increasingly entering clinical practice for solid tumors. » More on finanzen.net
Iovance Biotherapeutics accelerates revenue growth after successful launch of Amtagvi
Iovance Biotherapeutics is commercializing Amtagvi, the world’s first approved personalized TIL cell therapy for advanced melanoma. Rapid onboarding of specialized treatment centers and rising patient demand are driving dynamic revenue acceleration in the current fiscal year. Analysts view the first-mover advantage and the successful market entry as drivers for further operational growth. » More on finanzen.net
Iovance Biotherapeutics reaches 52-week high at $9.36
Iovance Biotherapeutics shares rose to a 52-week high of $9.36, delivering a year-to-date return of 215% and nearly a 279% gain over the past year; market capitalization is around $4.2 billion. In Q2 2026 the company reported record revenue of $99.31 million, driven by strong sales of the cancer therapy Amtagvi ($91 million), and an adjusted loss of $0.11 per share, beating expectations. UBS raised its price target to $7.00 (rating: neutral), TD Cowen increased its target to $10.00 and maintained buy; InvestingPro currently considers the stock overvalued. » More on de.investing.com
Iovance reports record Q2 revenue and reviews 2026 guidance on strong Amtagvi demand
Iovance reported record Q2 revenue of about $99.3 million, a 66% year-over-year increase driven by strong Amtagvi sales (U.S. Amtagvi ~$91M) and Proleukin ~$9M. Gross margin improved to 56% on higher volumes, manufacturing efficiencies and cost optimisation, while R&D expenses fell for a fourth consecutive quarter. Management is reviewing its 2026 revenue guidance of $350–370 million with an updated outlook expected in Q3, and continues expanding its treatment network to over 95 centres (forecasting at least 110 by year-end). The company finished the quarter with roughly $304 million in cash and is advancing multiple late‑stage clinical programmes and international regulatory submissions. » More on finance.yahoo.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 107.24m | 86.57% |
| Gross profit | 64.84m | 162.57% |
| Net profit | -19.66m | 74.71% |
| EBITDA | -10.74m | 83.90% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.14bn |
Number of shares | 462.66m |
52-week high/low | €13.98 - €1.89 |
| Dividends | No |
Beta | 0.76 |
P/E ratio | -14.08 |
PEG ratio | -0.15 |
P/B ratio | 4.19 |
P/S ratio | 9.11 |
Company profile
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
| Name | Iovance Biotherapeutics |
| CEO | Frederick G. Vogt |
| Headquarters | San Carlos,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 15/10/2010 |
| Employees | 975 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | IOVA |
London Stock Exchange | 0JDK.L |
Frankfurt | 2LB.F |
DĂĽsseldorf | 2LB.DU |
London | 0JDK.L |
MĂĽnchen | 2LB.MU |